Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $60.91 which represents a slight increase of $3.78 or 6.62% from the prior close of $57.13. The stock opened at $57.37 and ...

I'm Brandon Couillard, cover the life science tools and diagnostics sector here at the firm now. And it's my great pleasure to have Exact Sciences with us at the conference this year. Joining us ...

Air fryers continue to be popular, with many eager to own one. They're not just convenient; they can also save money as many opt to replace their ovens with them. However, there's still a lack of ...

The first Pléhouse skiing video ever The whole project was started in 2001 by three wellknown pro freeskiers Phil Larose Thomas Rinfret and Phil Bélanger EXACT SCIENCE brings you the progression ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Fintel reports that on August 27, 2024, Wells Fargo initiated coverage of Exact Sciences (NasdaqCM:EXAS) with a Overweight recommendation. Analyst Price Forecast Suggests 28.14% Upside As of ...